Rain Therapeutics Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Fremont CA United States (2017)

Organization Overview

First Clinical Trial
2019
NCT03805841
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Rain Therapeutics Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

milademetan (2 trials)

trabectedin (yondelis) (1 trial)

Drugs in Phase 2 Trials (2)

sotorasib (LUMAKRAS) (1 trial)

tarloxotinib (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4